Heartflow, Inc. Common Stock
HTFL
$49.88
+9.65%
HeartFlow, Inc. is a commercial-stage medical technology company that leverages artificial intelligence to provide non-invasive diagnostic solutions for coronary artery disease, primarily through its FFRCT, Roadmap, and Plaque Analysis software products. As a pioneer in AI-driven cardiac diagnostics, HeartFlow holds a unique competitive position in the healthcare information services industry, with a growing commercial footprint in the U.S. and Europe. The current investor narrative centers on the company's accelerating revenue growth and improving profitability, highlighted by its recent Q2 results and raised guidance, which have fueled a significant stock rally and attracted strong analyst optimism despite ongoing net losses.…
HTFL
Heartflow, Inc. Common Stock
$49.88
Investment Opinion: Should I buy HTFL Today?
Rating: Hold. HeartFlow is a high-growth company with strong momentum, but its current price exceeds analyst targets, suggesting limited upside in the near term. The consensus is 'strong buy' with an average target of $43.50, implying a -11% downside from the current price, which tempers enthusiasm.
Sign up to view all
HTFL 12-Month Price Forecast
HeartFlow's growth story is compelling, but the current valuation leaves little room for error. The stock's 80% surge in one month suggests momentum, yet the lack of profitability and high PS ratio (14.1x) make it vulnerable to corrections. I would upgrade to bullish if the company shows a clear path to profitability or if the stock pulls back to more reasonable levels. Conversely, a downgrade to bearish would occur if revenue growth decelerates or if the company faces significant competitive threats.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Heartflow, Inc. Common Stock's 12-month outlook, with a consensus price target around $44.78 and implied upside of -10.2% versus the current price.
Average Target
$44.78
0 analysts
Implied Upside
-10.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $55
Analyst target range
HeartFlow is covered by 8 analysts, with a consensus recommendation of 'strong buy' and a mean rating of 1.44. The average target price is $43.50, which implies a downside of -11.06% from the current price of $48.91, indicating that the stock has surpassed analyst expectations. The target range is $39.00 to $45.00, with the high target still below the current price, suggesting that analysts may need to revise their targets upward. The relatively narrow spread between low and high targets ($6.00) indicates moderate uncertainty, but the strong buy consensus reflects confidence in the company's growth story. However, the fact that the stock trades above the high target suggests that the market is pricing in even more optimistic scenarios than analysts, which could lead to volatility if expectations are not met.
Bulls vs Bears: HTFL Investment Factors
HeartFlow presents a compelling growth story with accelerating revenue, a high-margin software model, and a solid balance sheet, but it is trading at a significant premium to analyst targets and remains deeply unprofitable. The bull case is supported by strong momentum and improving fundamentals, yet the bear case highlights valuation risk and the potential for a sharp correction if growth disappoints. The most critical tension is whether the company can achieve profitability fast enough to justify its rich valuation, as any slowdown in revenue growth or margin improvement could trigger a de-rating. Currently, the evidence slightly favors the bull side given the strong growth trajectory and analyst optimism, but the risk-reward is skewed to the downside in the near term.
Bullish
- Accelerating Revenue Growth: HeartFlow's Q2 results and raised guidance indicate accelerating revenue growth, with estimated next-year revenue of $515.9 million. The stock surged 80% in the past month, reflecting strong market confidence in this trajectory.
- High Gross Margin Software Model: Gross margin stands at 76.8%, typical of scalable software businesses. This high margin provides a solid foundation for future profitability as revenue scales.
- Strong Balance Sheet and Liquidity: Debt-to-equity is only 0.073 and current ratio is 5.20, indicating minimal leverage and ample liquidity to fund operations and growth without financial distress.
- Improving Profitability Trajectory: Operating margin of -36.4% is better than net margin of -66.3%, showing progress toward profitability. Analysts estimate positive EPS of $0.61 for the next year, signaling a potential turnaround.
Bearish
- Stock Trades Above Analyst Targets: Current price of $48.91 exceeds the average analyst target of $43.50 by 12.4% and even the high target of $45.00 by 8.7%. This suggests the market has outpaced analyst expectations, increasing vulnerability to corrections.
- Deeply Negative Profitability: Net margin is -66.3% and trailing PE is -21.3, reflecting substantial losses. Despite improvements, the company remains unprofitable, and any slowdown in growth could pressure the stock.
- High Valuation with Limited Margin of Safety: PS ratio of 14.1x and EV/Sales of 19.7x are extremely high, pricing in significant future growth. Any disappointment in revenue or margin expansion could lead to multiple compression.
- Recent Price Surge May Be Overextended: The stock rose 80% in one month and 112.8% in six months, far outpacing the S&P 500. Such rapid gains often lead to profit-taking and short-term volatility.
HTFL Technical Analysis
HeartFlow's stock has exhibited a powerful uptrend over the past year, with a 1-year price change of +43.49%, significantly outperforming the S&P 500's +18.65%. The current price of $48.91 sits near the upper end of its 52-week range, at approximately 94.5% of the range (calculated as (48.91 - 20.13) / (51.778 - 20.13)), indicating strong momentum and investor confidence. This positioning near the highs suggests the stock is in a robust bullish phase, though it also raises the risk of short-term overextension.
Beta
—
—
Max Drawdown
-48.7%
Largest decline past year
52-Week Range
$20-$52
Price range past year
Annual Return
+50.4%
Cumulative gain past year
| Period | HTFL Return | S&P 500 |
|---|---|---|
| 1m | +67.1% | -1.1% |
| 3m | +50.1% | +3.0% |
| 6m | +143.4% | +15.4% |
| 1y | +50.4% | +16.2% |
| ytd | +72.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HTFL Fundamental Analysis
HeartFlow's revenue growth is accelerating, as evidenced by the recent Q2 results and raised guidance, which drove the stock's surge. While specific quarterly revenue figures are not provided, the company's market cap of $2.49 billion and PS ratio of 14.12x imply substantial revenue, and the estimated revenue for the next fiscal year is $515.9 million, suggesting a high growth trajectory. The company's gross margin is strong at 76.8%, indicating a scalable software model, but its net margin is deeply negative at -66.35%, reflecting significant operating losses. However, the operating margin of -36.39% shows improvement from the net margin, and the company is making progress toward profitability, as evidenced by the narrowing losses and positive analyst EPS estimates of $0.61 for the next year. HeartFlow's balance sheet is solid, with a debt-to-equity ratio of only 0.073, indicating minimal leverage, and a current ratio of 5.20, demonstrating ample liquidity. The company's ROE is -38.85%, reflecting current unprofitability, but its strong cash position and low debt provide a runway to fund growth. Free cash flow is not available, but the negative PCF ratio of -46.02 suggests the company is still burning cash, though at a manageable level given its liquidity.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HTFL Overvalued?
Given HeartFlow's negative net income, the PS ratio is the most appropriate valuation metric, and at 14.12x, it reflects the market's high growth expectations. The forward PE of -185.08 is not meaningful due to expected losses, but the PEG ratio of 2.03 suggests that the stock is priced for significant future growth. Compared to the industry average PS ratio (not provided), HeartFlow's multiple is likely at a premium, justified by its AI-driven technology and rapid adoption. Historically, without historical ratio data, it is difficult to assess whether the current valuation is high or low relative to its own past, but given the recent stock surge, it is likely near the upper end of its valuation band.
PE
-21.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-26.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant due to HeartFlow's ongoing losses. The net margin of -66.3% and operating margin of -36.4% indicate that the company is spending heavily to drive growth, resulting in negative cash flow (PCF ratio -46.0). While the balance sheet is strong with a debt-to-equity of 0.073 and current ratio of 5.20, the company's reliance on external funding could become problematic if capital markets tighten. Additionally, the high valuation (PS 14.1x) leaves little room for error; any revenue miss could lead to a sharp de-rating.